AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Splice Modulating Oligonucleotides as a Breast Cancer Therapy

Technology Benefits

Targets untreatable breast cancers - may be used to treat triple negative breast cancer since it expresses the prolactin receptor and there are no targeted therapies for this cancer. 75-95% reduction in the number, size and density of metastatic colonies 95% decrease in the number of cancer stem cells High Target Specificity - targets only one splice form of a receptor, signaling molecule, or transcription factor Non-Toxic - after up to 18 months of treatment, no signs of SMO toxicity in tissue samples

Detailed Technology Description

None

Application No.

9909128

Others

Applications

May be used to treat prostate and ovarian cancers since prolactin receptors are expressed in these cancers.
New class of therapeutic drugs that may be used to target other metastatic cancers and other indications triggered by alternative splicing

Background

Breast cancer is the most widely-diagnosed cancer in women. Over 266,000 women in the US will be diagnosed with breast cancer this year. Approximately 95% of breast cancers express prolactin receptors compared to 70% of breast cancers that express estrogen receptors. It is desirable to develop a therapy to target a common receptor expressed in ~95% of breast cancers.

Related Materials

T. Yonezawa, K. Chen, M. Ghosh, L. Rivera, R. Dill, L. Ma, P. Villa, M. Kawaminami, A. Walker, Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer Cancer Lett., 366 (2015), pp. 84–92

Tech ID/UC Case

27134/2012-794-3

Related Cases

2012-794-3

Country/Region

USA

For more information, please click Here